Br J Cancer:调节性T细胞可预测软组织肉瘤患者的临床结果

2021-06-15 xiaozeng MedSci原创

肿瘤微环境(TME)由多种细胞类型(如免疫细胞、成纤维细胞)和细胞外成分(如激素、细胞因子、生长因子)组成,其在宿主对肿瘤的免疫反应过程中起着至关重要的作用。

肿瘤微环境(TME)由多种细胞类型(如免疫细胞、成纤维细胞)和细胞外成分(如激素、细胞因子、生长因子)组成,其在宿主对肿瘤的免疫反应过程中起着至关重要的作用。

抗肿瘤反应的程度取决于T细胞抑制和激活信号之间的平衡,该过程主要通过免疫检查点标志物所介导。而在TME内,包括PD-1(程序性细胞死亡蛋白1)及其配体PD-L1在内的特定免疫检查点标志物的异常表达,通常会促进免疫耐受和肿瘤细胞的免疫逃逸。


既往研究显示,T细胞表面PD-1的表达升高以及PD-L1/PD-1通路的连续过度激活可减轻调节性T细胞(Tregs)的凋亡,并增强抗原特异性T细胞的凋亡。

软组织肉瘤(STS)通常被认为是非免疫原性的,尽管其特定的亚型对免疫疗法有反应。该研究旨在分析STS中肿瘤浸润淋巴细胞(TIL)和免疫检查点标志物,并评估其对该疾病的局部复发(LR)、远端转移(DM)以及患者的总生存期 (OS) 的预后影响


该回顾性研究共纳入了192名接受手术治疗的STS患者(中位年龄为63.5 岁,其中有103名男性(53.6%))。通过构建组织微阵列,对PD-1、PD-L1、FOXP3、CD3、CD4和CD8等标志物进行免疫组化分析。并分析TIL表型丰度和免疫检查点标记物与患者上述临床参数(LR、DM和OS)的相关性。

两种粘液纤维肉瘤的多光谱图像

研究人员发现,除FOXP3+和CD3-PD-L1+细胞亚群外,不同组织学亚型与所有免疫检查点标记物之间存在显著差异。相比于平滑肌肉瘤,粘液纤维肉瘤中发现了更高水平的PD-L1、PD-1和所有TIL表型。


进一步的研究发现,Tregs的存在与LR的风险升高相关,与手术切缘无关。其他TIL或免疫检查点标记物对患者的结果参数并无显著影响。

免疫检查点标记物和TIL表型的丰度取决于组织学亚型

总而言之,该研究结果发现,TIL和免疫检查点标记物在粘液纤维肉瘤中的水平最高。无论患者的手术切缘状态如何,高Treg水平均与患者的LR风险升高独立相关。


原始出处:

Smolle, M.A., Herbsthofer, L., Granegger, B. et al. T-regulatory cells predict clinical outcome in soft tissue sarcoma patients: a clinico-pathological study. Br J Cancer (14 June 2021).

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1898868, encodeId=45411898868b4, content=<a href='/topic/show?id=729322969b9' target=_blank style='color:#2F92EE;'>#临床结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22969, encryptionId=729322969b9, topicName=临床结果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4fd6156, createdName=oliver169, createdTime=Tue Nov 16 17:36:43 CST 2021, time=2021-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1420471, encodeId=910714204e1a2, content=<a href='/topic/show?id=2221935219e' target=_blank style='color:#2F92EE;'>#软组织#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93521, encryptionId=2221935219e, topicName=软组织)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=52913579937, createdName=qilu_qi, createdTime=Thu Jun 17 12:36:43 CST 2021, time=2021-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=974084, encodeId=71039e40842a, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=570d5526147, createdName=ms1000000906394680, createdTime=Wed Jun 16 14:12:34 CST 2021, time=2021-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=973885, encodeId=39b69e388531, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210615/49ed71c9ebbe4efab84b5b13e4ffdc4d/f76222ffae3944948a4c06e684458801.jpg, createdBy=89155326955, createdName=木燃, createdTime=Tue Jun 15 22:04:31 CST 2021, time=2021-06-15, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1898868, encodeId=45411898868b4, content=<a href='/topic/show?id=729322969b9' target=_blank style='color:#2F92EE;'>#临床结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22969, encryptionId=729322969b9, topicName=临床结果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4fd6156, createdName=oliver169, createdTime=Tue Nov 16 17:36:43 CST 2021, time=2021-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1420471, encodeId=910714204e1a2, content=<a href='/topic/show?id=2221935219e' target=_blank style='color:#2F92EE;'>#软组织#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93521, encryptionId=2221935219e, topicName=软组织)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=52913579937, createdName=qilu_qi, createdTime=Thu Jun 17 12:36:43 CST 2021, time=2021-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=974084, encodeId=71039e40842a, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=570d5526147, createdName=ms1000000906394680, createdTime=Wed Jun 16 14:12:34 CST 2021, time=2021-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=973885, encodeId=39b69e388531, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210615/49ed71c9ebbe4efab84b5b13e4ffdc4d/f76222ffae3944948a4c06e684458801.jpg, createdBy=89155326955, createdName=木燃, createdTime=Tue Jun 15 22:04:31 CST 2021, time=2021-06-15, status=1, ipAttribution=)]
    2021-06-17 qilu_qi
  3. [GetPortalCommentsPageByObjectIdResponse(id=1898868, encodeId=45411898868b4, content=<a href='/topic/show?id=729322969b9' target=_blank style='color:#2F92EE;'>#临床结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22969, encryptionId=729322969b9, topicName=临床结果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4fd6156, createdName=oliver169, createdTime=Tue Nov 16 17:36:43 CST 2021, time=2021-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1420471, encodeId=910714204e1a2, content=<a href='/topic/show?id=2221935219e' target=_blank style='color:#2F92EE;'>#软组织#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93521, encryptionId=2221935219e, topicName=软组织)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=52913579937, createdName=qilu_qi, createdTime=Thu Jun 17 12:36:43 CST 2021, time=2021-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=974084, encodeId=71039e40842a, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=570d5526147, createdName=ms1000000906394680, createdTime=Wed Jun 16 14:12:34 CST 2021, time=2021-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=973885, encodeId=39b69e388531, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210615/49ed71c9ebbe4efab84b5b13e4ffdc4d/f76222ffae3944948a4c06e684458801.jpg, createdBy=89155326955, createdName=木燃, createdTime=Tue Jun 15 22:04:31 CST 2021, time=2021-06-15, status=1, ipAttribution=)]
    2021-06-16 ms1000000906394680

    学习了

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1898868, encodeId=45411898868b4, content=<a href='/topic/show?id=729322969b9' target=_blank style='color:#2F92EE;'>#临床结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22969, encryptionId=729322969b9, topicName=临床结果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4fd6156, createdName=oliver169, createdTime=Tue Nov 16 17:36:43 CST 2021, time=2021-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1420471, encodeId=910714204e1a2, content=<a href='/topic/show?id=2221935219e' target=_blank style='color:#2F92EE;'>#软组织#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93521, encryptionId=2221935219e, topicName=软组织)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=52913579937, createdName=qilu_qi, createdTime=Thu Jun 17 12:36:43 CST 2021, time=2021-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=974084, encodeId=71039e40842a, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=570d5526147, createdName=ms1000000906394680, createdTime=Wed Jun 16 14:12:34 CST 2021, time=2021-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=973885, encodeId=39b69e388531, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210615/49ed71c9ebbe4efab84b5b13e4ffdc4d/f76222ffae3944948a4c06e684458801.jpg, createdBy=89155326955, createdName=木燃, createdTime=Tue Jun 15 22:04:31 CST 2021, time=2021-06-15, status=1, ipAttribution=)]
    2021-06-15 木燃

    学习

    0

相关资讯

Annamycin治疗软组织肉瘤,已获得FDA“孤儿药称号”

肉瘤是一类间充质细胞来源的罕见异质性恶性肿瘤,占所有成人恶性肿瘤的不到1%,占儿科癌症的12%。约80%的新发肉瘤来源于软组织,其余来源于骨。

Clin Cancer Res:3期试验| 阿霉素治疗对晚期软组织肉瘤患者的心脏毒性

阿霉素治疗对晚期软组织肉瘤患者的心脏毒性

Pembrolizumab在罕见组织肉瘤中提供临床益处!

II期AcSéPembrolizumab临床试验评估了Pembrolizumab单一疗法治疗罕见肉瘤的有效性和安全性。

治疗软组织肉瘤!君实生物PD-1获得FDA第3个孤儿药资格认定

9月17日,君实生物发布公告称其品特瑞普利单抗用于治疗软组织肉瘤获得FDA 颁发孤儿药资格认定,这是特瑞普利单抗获得的第3个孤儿药资格认定,此前特瑞普利单抗治疗黏膜黑色素瘤及鼻咽癌已分别获得 FDA

Eur Radiol:软组织肉瘤患者要警惕胸部转移的存在!

肺是软组织肉瘤转移最常见的部位,由于对肺转移性病灶进行手术切除可改善患者预后,因此,在最初诊断软组组肉瘤时应进行胸部CT扫描以明确肺转移病灶是否存在。